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Abstract
Background: White matter hyperintensities (WMH) of presumed vascular origin have been associated with an
increased risk of Alzheimer’s disease (AD). This study aims to describe the patterns of WMH associated with
dementia risk estimates and individual risk factors in a cohort of middle-aged/late middle-aged individuals (mean
58 (interquartile range 51–64) years old).
Methods: Magnetic resonance imaging and AD risk factors were collected from 575 cognitively unimpaired
participants. WMH load was automatically calculated in each brain lobe and in four equidistant layers from the
ventricular surface to the cortical interface. Global volumes and regional patterns of WMH load were analyzed as a
function of the Cardiovascular Risk Factors, Aging and Incidence of Dementia (CAIDE) dementia risk score, as well as
family history of AD and Apolipoprotein E (APOE) genotype. Additional analyses were performed after correcting for
the effect of age and hypertension.
Results: The studied cohort showed very low WMH burden (median 1.94 cm3) and 20-year dementia risk
estimates (median 1.47 %). Even so, higher CAIDE scores were significantly associated with increased global WMH
load. The main drivers of this association were age and hypertension, with hypercholesterolemia and body mass
index also displaying a minor, albeit significant, influence. Regionally, CAIDE scores were positively associated with
WMH in anterior areas, mostly in the frontal lobe. Age and hypertension showed significant association with WMH
in almost all regions analyzed. The APOE-ε2 allele showed a protective effect over global WMH with a pattern that
comprised juxtacortical temporo-occipital and fronto-parietal deep white matter regions. Participants with maternal
family history of AD had higher WMH load than those without, especially in temporal and occipital lobes.
Conclusions: WMH load is associated with AD risk factors even in cognitively unimpaired subjects with very low
WMH burden and dementia risk estimates. Our results suggest that tight control of modifiable risk factors in
middle-age/late middle-age could have a significant impact on late-life dementia.
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Introduction
White matter hyperintensities (WMH) are frequently
observed on T2-weighted magnetic resonance imaging
(MRI) sequences of healthy middle-aged and elderly in-
dividuals [1–3]. They are thought to be associated with
axonal loss and demyelination due to chronic ischemia,
and therefore are considered as surrogate markers of
cerebral small vessel disease, although their histopatho-
logical substrate might be heterogeneous [4, 5]. Multiple
risk factors of WMH are shared with Alzheimer’s disease
(AD) such as ageing, hypertension, hypercholesterol-
emia, and diabetes [6–10]. Moreover, WMH increase the
risk of cognitive decline and AD, contributing to its pro-
gression and severity [11–14]. As the therapeutic efforts
in the AD field progressively shift toward its prevention,
a better characterization of potentially modifiable con-
tributors to the burden of the disease is of the utmost
importance [3, 15].
Regarding hereditary risk factors for AD, the ε4 allele
of the apolipoprotein E (APOE) gene, the main genetic
risk factor for sporadic AD [16], has also been associated
with increased WMH load [17–23]. However, this asso-
ciation remains controversial [10, 24–26], possibly due
to heterogeneity in the methodological approaches. On
the other hand, fewer studies have analyzed the associ-
ation of AD family history and WMH load, again with
conflicting results. While some could not detect any re-
lationship with WMH [27, 28], others reported an in-
creased WMH load in participants with maternal family
history or with both parents affected [29].
The CAIDE (Cardiovascular Risk Factors, Aging, and
Incidence of Dementia) dementia risk score has been de-
veloped to predict the risk of dementia in 20 years
among middle-aged individuals [6]. This scale assigns
scores to participants on their characteristics, taking into
account some of the most important risk factors for de-
mentia (age, education, sex, systolic blood pressure, body
mass index (BMI), total cholesterol, physical activity,
and APOE status). Once a participant has their CAIDE
dementia risk score assigned, their risk of dementia after
20 years can be derived.
Associations between CAIDE scores and WMH have
been previously reported. One study found that
middle-aged participants with a CAIDE score above nine
had increased volumes of WMH 20 years later [30]. Re-
cently, those increments were reported to be only
present in deep white matter (DWM) [31]. However,
only one study has focused this analysis on cognitively
normal middle-aged subjects [32] and found that indi-
viduals at high risk (CAIDE > 9) showed higher WMH
burden, as measured with the semiquantitative Fazekas
visual scale, and that WMH mediated the relation be-
tween CAIDE with executive function as well as visual
perception and construction abilities.
Until recently, the literature has mainly concentrated on
global cerebral WMH measures. Lately, more studies have
started to focus on investigating the relevance of the topo-
graphical distribution of WMH [27, 33]. In those studies,
specific spatial patterns of WMH were related to relevant
vascular [33] and AD risk factors [18]. Moreover, stra-
tegically located WMH might have an impact on cogni-
tion [34, 35] and increase the risk of developing AD [36].
Most of those studies, however, were carried out with rela-
tively old and/or cognitively impaired participants, often
presenting with several comorbidities.
In the present study, we sought to investigate the associ-
ation between global and regional WMH burden and
CAIDE dementia risk score in a cohort of middle aged/
late middle-aged cognitively healthy participants enriched
for heritable AD risk factors. The fact that our participants
are younger and cognitively healthier than the ones in pre-
vious studies allow us to better understand the role of
modifiable and nonmodifiable risk factors of dementia
into WMH burden and distribution, without the mixtur-
ing effect of other comorbidities. Therefore, global and re-
gional associations between WMH and each individual
risk factor included in the CAIDE scale, including the
APOE genotype, as well as family history of AD have been
studied.
Methods
Participants
Participants in this study are part of a wider research
platform: the ALFA cohort (for ALzheimer and FAm-
ilies). With the aim of tracking the evolution of the AD
continuum in asymptomatic individuals, the ALFA co-
hort is composed of 2743 cognitively normal partici-
pants, many of them adult children of patients with AD,
aged between 45 and 75 years. The ALFA study protocol
was approved by the Independent Ethics Committee
Parc de Salut Mar Barcelona (and registered at Clinical-
trials.gov, NCT01835717). For a full detailed description
of the cohort see Molinuevo et al. [37]. In brief, partici-
pants had a Clinical Dementia Rating (CDR) score [38]
equal to 0 and scored within the established cut-offs for
the neuropsychological battery that included the
Mini-Mental State Examination (MMSE) ≥ 26, Memory
Impairment Screen (MIS) ≥6 [39, 40], Time-Orientation
subtest of the Barcelona Test II (TO-BTII) ≥68 [41], and
semantic fluency (animals, SF) ≥12 [42, 43]. Exclusion
criteria for these participants included major psychiatric
disorders or other diseases that could affect cognition,
neurological disorders, brain injury that could affect cog-
nition, or family history of AD with suspected autosomal
dominant pattern.
A subgroup of 608 ALFA participants without MRI
contraindications was selected to participate in the
present study according to their APOE genotype,
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preferentially including APOE-ε4 and APOE-ε2 carriers
[44]. The rest of the participants were selected to try
and match the previous subjects by age and sex. The
MRI study protocol, registered at Clinicaltrials.gov
(NCT02198586), has been conducted in accordance with
the directives of the Spanish Law 14/2007, of 3 July, on
Biomedical Research (Ley 14/2007 de Investigación Bio-
médica). All participants accepted the study procedures
by signing an informed consent form.
From the 608 participants invited to participate in this
study, 595 agreed to undertake MRI scans and 575 pro-
vided valid MRIs. The most important issue for valid
MRI acquisition was claustrophobia (n = 16 drop-outs),
followed by three participants of incompatible physical
size or shape that precluded lying in the scanner, and an
image artifact caused by irremovable metallic earrings
(n = 1). Finally, we also have to remove the scans of 14
participants from this study due to the presence of inci-
dental findings [2], problems in motion artifacts, or seg-
mentation problems that prevented us correctly
segmenting WMH. Therefore, a total of 561 images were
available for subsequent analyses.
Sociodemographic, anthropometric, lifestyle, and clinical
factors
Basic sociodemographic and clinical data were registered
either during the clinical interview or through on-line,
self-administered questionnaires. All participants were
asked about their family and personal medical history,
and medication use was recorded. Participants were con-
sidered to be ‘hypertensive’ if at least one of the follow-
ing conditions was met: 1) participant self-reported
diagnosis; 2) current use of medication; 3) measured sys-
tolic blood pressure above 140 mmHg. Analysis of global
and regional WMH load for each of these conditions is
shown in Additional file 1. Note that, only condition 3
was used for the derivation of the CAIDE score (see the
CAIDE dementia risk score derivation section below).
‘Hypercholesterolemia’ was categorized as present if at
least one of the first two aforementioned conditions for
hypertension were met.
BMI was derived from the height and weight measured
at the time of the interview. Physical activity was mea-
sured using the Spanish short version of the Minnesota
Leisure Time Physical Activity Questionnaire [45], and
participants were split into two categories: ‘active’ or ‘in-
active’. A participant was considered to be active if he/
she did more than 150 min of moderate exercise or 75
min of vigorous exercise per week as recommended by
current guidelines.
CAIDE dementia risk score derivation
The previously mentioned factors were used to derive
the probability of dementia in 20 years using the CAIDE
dementia risk score [6], as explained previously [17]. In
brief, CAIDE takes into account the age, education, sex,
systolic blood pressure, BMI, total cholesterol, and phys-
ical activity in the first model (CAIDE-I), and also APOE
status in the second model (CAIDE-II). Only the first
model is reported in this study due to a high similarity
in the results of both models. In addition, CAIDE-II only
considers whether an individual carries a copy of the ε4
allele, whereas in our study we sought differences among
all combinations of alleles (see the APOE genotyping
section below).
For the calculation of CAIDE dementia risk scores, each
participant was assigned some points or scores depending
on the aforesaid characteristics. Additional file 1 Table S1
summarizes the risk factors taken into account and the
correspondent scores assigned to the participant for those
characteristics. Once the total CAIDE dementia risk score
is calculated, a percentage risk of dementia 20 years later
can be derived using a nonlinear expression that can be
found in the reference paper [6].
All the necessary information to derive CAIDE de-
mentia risk scores was registered in the ALFA cohort
with the exception of total cholesterol in blood. To take
into account this measure, we assigned 2 points (as with
participants with > 6.5 mmol/l in the original CAIDE
derivation) to those participants who reported to be di-
agnosed with hypercholesterolemia or to be taking medi-
cation to control it. Regarding hypertension status, we
used the same criterion as in the original paper, classify-
ing as hypertensive those participants with systolic blood
pressure above 140 mmHg. All the rest of the CAIDE
scores were assigned as in the original work.
APOE genotyping
Total DNA was obtained from the blood cellular frac-
tion by proteinase K digestion followed by alcohol pre-
cipitation. Using the following primers (APOE-F 5′
-TTGAAGGCCTA CAAATCGGAACTG-3′ and APOE-R
5′ -CCGGCTGCCCAT CTCCTCCATCCG-3′) samples
were genotyped for two single nucleotide polymor-
phisms (SNPs), rs429358 and rs7412, determining the
possible APOE alleles: ε1, rs429358 (C) + rs7412 (T); ε2,
rs429358 (T) + rs7412 (T); ε3, rs429358 (T) + rs7412 (C);
and ε4, rs429358 (C) + rs7412 (C). All allele combina-
tions were considered as separate categories for subse-
quent statistical analyses.
Family history of AD
Family history of AD was recorded as previously re-
ported [37]. In brief, family history was divided into four
possible groups: ‘maternal’, ‘paternal’, ‘both parents’, and
‘no AD family history’. This classification was only con-
sidered positive if the antecedent relative was younger
than 75 years at the time AD was diagnosed.
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MRI acquisition
MRIs were acquired on a 3.0-T scanner (GE Discovery
MR750 W 3T). The same protocol, which included one
T1- and three T2-weighted sequences, was performed on
all participants. The T1-weighted sequence had an isotropic
voxel size of 1mm3 with a matrix size of 256 × 256 × 160
(TR/TE/TI = 8.0/3.7/450ms, NSA = 1, flip angle = 8°). T2
and T2*-weighted sequences, with a voxel size of 1 × 1 × 3
mm, were as follows: fluid attenuation inversion recovery
(FLAIR: TR/TE/TI = 11,000/90/2600ms, flip angle = 160°),
fast spin echo (TR/TE = 5000/85ms, flip angle = 110°), and
gradient echo (GRE: TR/TE = 1300/23ms, flip angle = 15°).
All scans were visually assessed for quality and incidental
findings by a trained neuroradiologist [2].
WMH visual assessment
All MRIs were visually assessed by a trained neuroradi-
ologist who was blinded to the APOE genotype of the
participants. All images were rated using modifications
of the Fazekas Scale [46], which separately categorizes
the severity of deep and periventricular lesions on a scale
from 0 to 3 (0, none or a single punctate WHM lesion;
1, multiple punctate lesions; 2, beginning confluency of
lesions (bridging); and 3, large confluent lesions).
WMH segmentation and quantification
WMH were automatically segmented using a Bayesian
algorithm [47]. In brief, T1-weighted, T2-weighted, and
T2-FLAIR images are rigidly coregistered using the Nif-
tyReg package [48]. The data are then modeled as a
multivariate Gaussian mixture model that simultan-
eously accounts for healthy tissue and unexpected obser-
vations and is constrained by participant-specific
statistical tissue priors derived from the Geodesic Infor-
mation Flows (GIF) algorithm [49].
The number of required Gaussian components is dy-
namically determined at a patient level to ensure a bal-
ance between model fit and complexity using the
Bayesian Inference Criterion. Once the model has con-
verged, a postprocessing step is applied to extract prob-
ability maps of candidate lesion voxels that are then
further corrected for spurious false positive detection
using the output of the parcellation algorithm to avoid
regions prone to artefacts. Volumetric measurements are
derived as the sum of this probability map over a region
of interest.
This method was applied only for supratentorial re-
gions, therefore excluding cerebellar and brainstem
areas. We also calculated the total intracranial volume
(TIV) for normalization purposes. This measure was de-
rived automatically using a previously described method
[49], and it included total brain volume comprising also
ventricles and cerebrospinal fluid (CSF) .
To depict regional results, we used a bullseye repre-
sentation [50] (excluding infratentorial regions). Every
sector of the bullseye represents one lobar white matter
segment obtained based on the cortical parcellation out-
put from the GIF algorithm. Another unique region was
the basal ganglia (including internal capsule and the
thalamus). The concentric rings in the bullseye plot are
defined by dividing the area between the ventricular sur-
face and the cortical sheet into four equidistant layers.
The interior layer in the plot represents the most peri-
ventricular area and the most external layer corresponds
to the juxtacortical regions. The final representation is
formed of 36 regions that are composed of nine-lobar
segmentation with four layers each. Figure 1 shows an
example of the segmentation for one participant.
Statistical analyses
We sought to assess the association between global and
regional WMH load with CAIDE-I scores and with each
of the individual risk factors included in the scale,
namely age, hypertension, hypercholesterolemia, BMI,
sex, education, and physical exercise. We also assessed
the association with APOE genotype and family history
of AD. All the analyses had the WMH percentage of the
TIV as an outcome variable to account for total brain
size. The distribution of the main dependent variables
(global and regional WMH load) was significantly differ-
ent from normal (Additional file 1: Figure S1A), as well
as after log-transformation. For this reason, we used
nonparametric statistics for all the analyses.
First, we tested the cross-correlation between CAIDE
percentage risk of dementia and its individual risk fac-
tors. To do so, we used Spearman’s rank test (continu-
ous vs. continuous), Mann-Whitney U test (continuous
vs. dichotomous), and χ2 test (dichotomous vs. dichot-
omous). The effect size for each of these tests were
Spearman’s rho, Cohen’s d, and φ, respectively.
Then we sought associations between WMH load and
independent variables, also using nonparametric tests:
Spearman’s rank correlation for continuous variables
and Mann-Whitney U test for dichotomous variables.
To test the associations of CAIDE we used the percent-
age risk of having dementia as a predictor.
We also analyzed the association between global and
regional WMH load against APOE and family history of
AD. As these variables had more than two groups all
comparisons were performed against a reference group.
In APOE analysis we compared all the genotypic groups
to APOE-ε3/ε3 participants (except for ε2 homozygotes
due to a low number). When comparing family history
of AD, those participants without family history of AD
were set as reference group.
A modified bootstrap method was used to calculate
p values. We randomly assigned the outcome variables to
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the original predictors 10,000 times, without resampling,
and for each re-assignation we calculated the Spearman’s
rho or z statistic. Then p values were estimated by calcu-
lating the number of times the statistic was higher/lower
(two-sided test) than the statistic calculated with the ori-
ginal data, and then dividing by the number of permuta-
tions done. The threshold for statistical significance was
set to p < 0.05 false discovery ratio (FDR)-corrected. The
effect size shown in the figures is either Spearman’s rho or
Cohen’s d, depending on the nature of the variable (con-
tinuous or categorical).
Three different statistical models were used in all the
studied comparisons. In the first model, no covariates
were included to show the direct associations between
WMH and the predictors. In the second model, we cor-
rected for the effect of age and, in the last one, for
hypertension status, but not age. The reason for correct-
ing for these two factors was two-fold. First, they were
expected to be the main drivers of the association of
CAIDE and WMH and, second, some groups created for
dichotomous variables (e.g., women/men) differed sig-
nificantly on one of these two main risks (see Additional
file 1: Tables S1–S6). Therefore, correcting by these two
important confounders is expected to provide more
comparable results of the analysis of risk factors in
groups unbalanced for them. Finally, we only report here
the groups showing significant results for APOE and
family history of AD analyses.
Results
The sociodemographic and clinical information of the
561 participants is presented in Table 1. CAIDE demen-
tia risk score was low [6, 30–32] due to the low preva-
lence of hypercholesterolemia, BMI higher than 30 kg/
m2, the high number of active subjects, and the high
education of the participants [37]. Due to the recruit-
ment strategy of the MRI study, there was a high pro-
portion of APOE-ε2 and APOE-ε4 participants and,
more specifically, APOE-ε4 homozygotes. Likewise, a
high proportion of participants also presented a family
history of AD, more often from the maternal side.
Correlations among CAIDE and its individual compo-
nents are shown in Additional file 1: Figure S2. CAIDE
showed a high correlation with all risk factors included
in its calculation, as was expected. Among individual
risk factors, age was significantly and positively associ-
ated with hypertension, hypercholesterolemia, and BMI,
and negatively to education. Male sex was significantly
Fig. 1 Example of the brain segmentation for one participant. Different axial slices of the same participant are shown in each column. The first
row shows WMH lesion segmentation in green. In the second row, lobar segmentation is shown. Finally, the last row shows the four layers in
which each lobe was segmented. Of these layers, the most internal represents periventricular areas, there are two layers of DWM and finally a
juxtacortical layer which is the most external
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associated with higher prevalence of hypertension as
well as with higher BMI and education.
WMH burden was low [27, 33, 36] as, on average,
it only covered a volume of 1.94 cm3 corresponding
to 0.14% of the TIV. Only 8% of our cohort reached
pathological levels of WMH with the Fazekas scale (≥ 2
score on this age range) [46]. Regarding the spatial distri-
bution of WMH, the most affected regions were periven-
tricular areas and the occipital lobe (Additional file 1:
Figure S1C).
Global analysis
The CAIDE percentage risk of dementia was signifi-
cantly associated with global WMH (Model 1, effect size
0.11, 95% confidence interval (CI) 0.03–0.19, p = 0.017;
Table 2). However, this association became nonsignifi-
cant after adjusting for the effect of age or hypertension
status (Models 2 and 3, respectively).
In Model 1 (without covariates) the main drivers of the
association between CAIDE percentage risk of dementia
and global WMH load were age (effect size 0.22, 95% CI
0.13–0.29, p < 0.001) and hypertension (effect size 0.14,
95% CI 0.05–0.22, p < 0.001). For the hypertension assess-
ment, the condition was more highly correlated with
global WMH burden with the use of medication to con-
trol hypertension (Additional file 1: Table S2). Hyperchol-
esterolemia also displayed a significant effect (effect size
0.09, 95% CI 0.00–0.17, p = 0.042) and BMI showed a
trend to significance (effect size 0.08, 95% CI −0.00 to
0.16, p = 0.053). In this direct model we also found lower
WMH burden in APOE-ε2/ε3 participants than in the ref-
erence APOE-ε3/ε3 group (effect size −0.13, 95% CI −0.24
to −0.01, p = 0.042). However, the APOE-ε2/ε3 group was
significantly younger than the reference group (56 vs
60 years old; p < 0.001, Additional file 1: Table S7)
and, when corrected by age (Model 2), this compari-
son did not achieve significance. The rest of the com-
parisons between groups of APOE or family history of
AD showed nonsignificant differences on WMH load.
In Model 2 (adjusted by age), of the CAIDE risk factors
only hypertension remained significantly associated with
global WHM (effect size 0.09, 95% CI 0.00–0.17, p = 0.017),
even though hypertensive and nonhypertensive partic-
ipants were significantly different in age (62 vs 56
years old; p < 0.001, Additional file 1: Table S3). In
this model, we also found a significant increase in
global WMH load in those subjects with a maternal family
history of AD (effect size 0.12, 95% CI 0.03–0.21, p = 0.024).
This group also showed differences in age with respect to
the reference group. Participants with a family history of AD
were significantly younger than those without (55 vs 60 years
old; p < 0.001, Additional file 1: Table S8).
Finally, in Model 3 (adjusted by hypertension), only
age from the CAIDE variables remained significantly as-
sociated with global WMH (effect size 0.18, 95% CI
0.09–0.26, p < 0.001). Maternal family history of AD was
also significant in Model 3 (effect size 0.08, 95% CI
−0.01 to 0.18, p = 0.040).
Table 1 Sociodemographic and clinical characteristics of ALFA
participants
Sociodemographic and clinical variables
(n = 561)
Mean /
n
Interquartile range
/ %
CAIDE-I risk (%) 1.47 0.67–3.22
CAIDE-I score (0–15) 6 4–8
Age (years) 58 51–64
Hypertension, n (%) 147 26.2
Hypercholesterolemia, n (%) 171 30.5
BMI (kg/m2) 26.4 24.0–29.4
Sex (male), n (%) 219 38.9
Education (years) 14 11–17
Physical exercise, n (%)
Active 368 65.6
Not active 148 26.4
Not available 45 8.0
APOE genotype, n (%)
ε4/ε4 71 12.7
ε4/ε3 170 30.3
ε3/ε3 159 28.3
ε2/ε4 45 8.0
ε2/ε3 109 19.4
ε2/ε2 7 1.2
Family history of AD, n (%)
Maternal 190 33.9
Paternal 91 16.2
From both 16 2.9
None 245 43.7
Not available 19 3.4
Fazekas Scale, n (%)
Score 0 269 48.0
Score 1 247 44.0
Score 2 43 7.7
Score 3 2 0.4
Total WMH load (cm3) 1.94 1.13–3.69
Total WMH load/TIV (%) 0.14 0.08–0.26
MMSE 29 28–30
Time difference between visit and MRI
(days)
307 251–366
Values are expressed as median (interquartile range) unless
otherwise indicated
AD Alzheimer’s disease, APOE apolipoprotein E, BMI body mass index, CAIDE
Cardiovascular Risk Factors, Aging, and Incidence of Dementia, MMSE Mini-
Mental State Examination, MRI magnetic resonance imaging, TIV total
intracranial volume, WMH white matter hyperintensities
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Regional analysis
CAIDE percentage risk of dementia was significantly as-
sociated with anterior WMH, specifically in all frontal
lobe and parietal DWM (layers 2 and 3) in Model 1
(Fig. 2, first column). Periventricular WMH in the tem-
poral lobe and basal ganglia also showed significant in-
crements with higher CAIDE percentage risk of
dementia.
Regarding individual factors, age and hypertension
showed the highest effect sizes in line with the global
analysis. They both showed a widespread association
across almost all regions of the brain. The use of
medication for controlling hypertension was the
condition most highly correlated with WMH from
those considered for assessing hypertension, with al-
most all regions having a significant and high effect
(Additional file 1: Figure S3). Hypercholesterolemia
also displayed significant widespread associations with
WMH but with lower effect sizes. BMI showed sig-
nificant associations with periventricular WMH in the
frontal, parietal, and temporal lobes, as well as with
DWM lesions in the frontal lobe. Consistent with the
CAIDE analysis, we found a negative association be-
tween BMI and WMH in one of the external layers
of the basal ganglia. Women displayed a juxtacortical
pattern of higher WMH load in all lobes compared
with men. The effect of education reached signifi-
cance in the frontal external layers, with higher edu-
cation being protective against WMH. Finally,
physical exercise did not show any significant associ-
ation with WMH.
The middle and right columns of Fig. 2 show the re-
sults after correcting for age (Model 2) and hypertension
(Model 3) for CAIDE and individual risk factors. CAIDE
percentage risk showed only a negative association with
WMH in basal ganglia when corrected for age (Model
2). Negative associations, but now in the parietal lobe,
remained when we accounted for hypertension status
(Model 3). All these regions became nonsignificant if
any secondary driver (BMI or hypercholesterolemia) was
included in the model (data not shown).
Age and hypertension still showed significant re-
gional WMH associations after correction by the
other variable (Model 3 and Model 2, respectively). In
Model 3, age was significantly correlated with WMH
burden in almost all the same regions as with Model
1. However, a negative association appeared in the
juxtacortical layer of the temporal lobe in this model,
as in the CAIDE analysis. Internal and DWM layers
of anterior areas showed a significant association with
hypertension in Model 2 (age-corrected). Also, some
DWM of temporal and occipital regions remained sig-
nificantly associated.
BMI and hypercholesterolemia were highly correlated
with hypertension in our sample (p < 0.001, Additional
file 1: Figure S2 and Table S4) and, accordingly, the dir-
ect pattern of WMH (Model 1) disappeared (BMI) or
was reduced (hypercholesterolemia) when adjusting by
this factor (Model 3). Hypercholesterolemia was also
highly correlated with age (Additional file 1: Table S4),
and when we corrected for this factor only juxtacortical
areas of the frontal and parietal lobes remained above
the significance threshold.
Sex differences in juxtacortical areas remained after
controlling for age or hypertension status (Models 2 and
3) which is relevant as, in our cohort, hypertension was
Table 2 Associations between global WMH and AD and WMH risk factors
Model 1 (Direct) Model 2 (Age-corrected) Model 3 (Hypertension-corrected)
Effect size (95% CI) p Effect size (95% CI) p Effect size (95% CI) p
CAIDE-I 0.11 (0.03 to 0.19) 0.017 0.01 (−0.07 to 0.09) 0.423 0.01 (−0.08 to 0.09) 0.444
Age 0.22 (0.13 to 0.29) < 0.001 – – 0.18 (0.09 to 0.26) < 0.001
Hypertension 0.14 (0.05 to 0.22) < 0.001 0.09 (0.00 to 0.17) 0.017 – –
Hypercholesterolemia 0.09 (0.00 to 0.17) 0.042 0.05 (−0.04 to 0.14) 0.207 0.07 (−0.02 to 0.15) 0.051
BMI 0.08 (−0.00 to 0.16) 0.053 0.06 (−0.02 to 0.14) 0.207 0.03 (−0.05 to 0.11) 0.249
Sex (Men) −0.01 (−0.09 to 0.08) 0.411 −0.01 (−0.10 to 0.07) 0.423 −0.03 (−0.11 to 0.05) 0.246
Education −0.04 (−0.13 to 0.04) 0.192 −0.01 (−0.09 to 0.08) 0.423 −0.02 (−0.11 to 0.06) 0.313
Physical exercise −0.04 (−0.13 to 0.04) 0.192 −0.05 (−0.14 to 0.03) 0.207 −0.02 (−0.10 to 0.07) 0.352
Maternal family history of AD* 0.12 (−0.02 to 0.17) 0.077 0.12 (0.03 to 0.21) 0.024 0.08 (−0.01 to 0.18) 0.040
APOE-ε2/ε3* −0.13 (−0.24 to -0.01) 0.042 −0.08 (−0.20 to 0.04) 0.2077 −0.10 (−0.21 to 0.02) 0.054
The three models had WMH/TIV (%) as an outcome variable; no covariates were used in Model 1; age effect was corrected for in Model 2 and hypertension was
accounted for in Model 3
Significant results are shown in bold (p < 0.05, false discovery ratio-corrected)
Participants without a family history of AD and APOE-ε3 homozygotes were the reference group for group comparisons
AD Alzheimer’s disease, APOE apolipoprotein E, BMI body mass index, CAIDE Cardiovascular Risk Factors, Aging, and Incidence of Dementia, CI confidence interval,
TIV total intracranial volume, WMH white matter hyperintensities
*All other pairwise group comparisons showed no significant associations and are not shown in the table
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Fig. 2 Regional patterns of WMH associations with CAIDE-I and each of the individual risk factors included in the scale. The individual risks of CAIDE-I are:
age, hypertension, hypercholesterolemia, body mass index, sex, education, and physical exercise. Model 1 shows direct correlations without covariates (first
column). Model 2 and Model 3 show correlations against WMH correcting by age and hypertension, respectively (second and third column). Effect sizes of
the correlation are colored only on regions that showed significant association (p< 0.05 FDR-corrected). Hot colors represent positive correlations between
WMH and each particular condition, and cold colors negative associations. In dichotomic comparisons, hypertensive, hypercholesterolemic, men, and active
participants were set as reference groups. *Model of reference due to demographic characteristics of this group. BG basal ganglia, CAIDE-I Cardiovascular
Risk Factors, Aging, and Incidence of Dementia percentage risk of dementia (model without APOE), FL left frontal lobe, FR right frontal lobe, PL left parietal
lobe, PR right parietal lobe, OL left occipital lobe, OR right occipital lobe, TL left temporal lobe, TR right temporal lobe
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less prevalent in women than in men (21.3% vs 33.8%;
p < 0.001, Additional file 1: Table S5).
Higher levels of education and physical exercise were
associated with lower regional WMH load in juxtacorti-
cal layers of the anterior areas. For education, the frontal
areas remained significant in all three models. This is
remarkable since age and education were negatively
correlated in our cohort (Additional file 1: Figure S2). In
the case of physical exercise, the only model that showed
regional WMH burden associations was Model 2 (age-
corrected). However, that was the best model for this
variable as age was significantly different for participants
not physically active vs physically active (56 vs 58 years
old; p = 0.069, Additional file 1: Table S6).
Figure 3 shows the regional analysis with hereditary
AD risk factors. APOE group differences were only sig-
nificant in APOE-ε2 carriers. They showed a protective
effect against WMH in external white matter layers of
all lobes. Differences were more pronounced in Model 1
because APOE-ε2 carriers were significantly younger
than APOE-ε3/ε3 individuals in our cohort (56 vs 60
years old; p < 0.001, Additional file 1: Table S7). There-
fore, Model 2 that corrected for the between-group dif-
ference in age should be regarded as the model of
reference. It has to be noted that APOE-ε2 carriers also
differed to APOE-ε3/ε3 individuals in the proportion of
participants with hypercholesterolemia (15.5% vs 32.9%;
p = 0.001, Additional file 1: Table S7).
Finally, we only found regional differences in WMH
load in those subjects with a maternal family history of
AD against those without. In these subjects, increased
WMH burden was detected mainly in the temporal and
occipital areas, but also in the juxtacortical frontal, par-
ietal, and basal ganglia areas. The group of participants
with a maternal family history of AD were younger than
the group without a family history in our cohort (55 vs
60 years old; p < 0.001, Additional file 1: Table S8).
Therefore, for this comparison, Model 2 should be
regarded as the reference since it accounted for the
between-group differences in age.
Discussion
Global analysis
In this study, we sought to extend previous findings
reporting associations between AD risk factors against
global and regional patterns of WMH in a relatively
younger and cognitively unimpaired sample. Even
though our middle-aged/late middle-aged participants
displayed very low WMH burden compared with previ-
ously studied clinical cohorts [27, 33, 36] and a low de-
mentia risk, a significant association was found between
CAIDE and global WMH load. Higher WMH burden
with increased CAIDE dementia risk scores are in line
with previous literature in late-life [30, 31] and in
late-midlife participants with mild cognitive impairment
and subjective cognitive decline [51]. The fact that
Fig. 3 Regional patterns of WMH correlation with APOE and family history of AD. These models show correlations without any covariate (Model
1), correcting for age (Model 2), and correcting for hypertension (Model 3). Effect sizes of the correlation are shown only on regions that
presented significant association (p < 0.05 FDR-corrected). Hot colors represent positive correlations between WMH and each particular condition,
and cold colors negative associations. APOE-ε3ε3 carriers and participants without family history of AD were set as reference group. *Model of
reference due to demographic characteristics of this group. AD Alzheimer’s disease, APOE apolipoprotein E, BG basal ganglia, FL left frontal lobe,
FR right frontal lobe, PL left parietal lobe, PR right parietal lobe, OL left occipital lobe, OR right occipital lobe, TL left temporal lobe, TR right
temporal lobe
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similar results were obtained in our younger sample of
cognitively unimpaired participants suggests that in-
creased WMH load might be an early mechanism
through which cardiovascular factors increase the risk of
dementia [12, 52, 53]. This effect did not survive correc-
tion by age, thus suggesting that this association is either
directly mediated by age or by age-related factors.
As expected, there was an association between hyper-
tension and global WMH load that survived correction
by age. This result suggests that tight control of systolic
hypertension in midlife might be an effective strategy to
prevent late-life cognitive decline. Recently published re-
sults from a randomized clinical trial (SPRINT-MIND)
[54] in individuals with increased cardiovascular risk, but
without diabetes, showed that control of systolic blood
pressure below 120mmHg resulted in 19% fewer cases of
mild cognitive decline over 3 years [55]. Indeed, additional
evidence supports that the effect of cardiovascular disease
on brain health is stronger in midlife [56, 57].
Regional analysis
Our regional analysis of WMH distribution also showed
interesting results. We observed that the CAIDE per-
centage risk of dementia was significantly correlated
with WMH load in frontal and deep parietal areas.
DWM in these territories is irrigated by the distal
branches of superficial perforating arterioles of the an-
terior cerebral artery and the superior division of the
middle cerebral artery. Our result suggests that early
small vessel disease, specifically in these territories,
might prompt future cognitive decline in a particularly
severe way. Actually, previous reports have shown that
parietal WMH burden is associated with increased risk
of AD [58], whereas frontal WMH is associated with
nonspecific cognitive impairment [36, 59]. It is unclear,
however, whether this regional pattern is linked to
mechanisms related to the distinct features of the arteri-
olar wall and/or perivascular space in deep white matter,
or just reflect increased susceptibility of these areas to
small vessel disease at the earliest stages [60].
Regarding individual AD risk factors, age and hyper-
tension displayed the strongest and most widespread as-
sociation with WMH load, consistent with previous
reports [33, 61], especially in the anterior regions and in
line with a recent study [62]. The comparison of the re-
sults before and after accounting for the effect of these
two main drivers of WMH burden allowed us to reveal
specific patterns of WMH load in association with the
other risk factors. Both risk factors showed significant
regional associations with WMH burden once corrected
for the other. This result illustrates that even though
they were highly correlated (Additional file 1: Figure S2),
their association with WMH load seems to be independ-
ent, at least regionally.
We also found interesting results when we looked at the
association of regional WMH burden and the three cri-
teria used to assess hypertension. Records of antihyperten-
sive medication were more strongly associated with this
regional pattern of WMH load than self-reported clinical
history of hypertension or a systolic blood pressure over
140mmHg (Additional file 1: Figure S3). This result sup-
ports the criteria selected here to define hypertension for
the study of its impact on WMH burden.
The frontal lobe was particularly sensitive to factors
associated with healthy lifestyle habits, such as BMI,
hypercholesterolemia, education, or physical exercise.
Education and physical exercise showed a protective ef-
fect on frontal WMH load, as previously reported [33],
whereas BMI and hypercholesterolemia had a negative
impact on WMH burden. However, all these factors
apart from physical exercise were highly correlated with
hypertension in our sample (p < 0.001, Additional file 1:
Figure S2), and the pattern of the WMH effect disap-
peared when adjusting for this factor (Model 3).
Regarding nonmodifiable factors other than age, fe-
male sex was associated with higher juxtacortical
WMH load than male sex. A greater WMH burden
in women may seem counterintuitive given that men
tend to have a worse vascular risk factor profile (as
actually occurred in our sample: 21.3% hypertensive
women vs 33.8% men; p = 0.001, Additional file 1:
Table S5). Nevertheless, this result survived correction
for hypertension and is in agreement with previous
studies [1, 63, 64] showing females to have more le-
sions than men, especially across the external layers
of white matter [33] that persists even after adjust-
ment for midlife vascular risk factors [63]. Some of
the possible explanations previously proposed for
these results were a higher prevalence of arterial stiff-
ness in women than in men and sexual differences in
white matter microstructure [63].
Regarding APOE, we found the ε2 allele to be protect-
ive against WMH. This effect was present in all brain
lobes either in DWM or juxtacortical areas. It could be
speculated that the APOE-ε2 protective effect is exerted
through the protective effect of this allele against hyper-
cholesterolemia. Consistent with this hypothesis, the
APOE-ε2 group in our cohort had a significant lower
proportion of hypercholesterolemic participants (15.5%
vs 32.9%; p = 0.001, Additional file 1: Table S6) and the
regional pattern of WMH associations with these two
factors was very similar (see the first column of Figs. 2
and 3).
Although we expected a higher prevalence of patho-
logical WMH burden for APOE-ε4 homozygotes looking
at previous studies using the same sample [17], we only
found a statistically non-significant increase in WMH
load in this group. A possible explanation reconciling
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the nonsignificantly increased WMH load in this volu-
metric study and our previous finding of higher patho-
logical levels of WMH in APOE-ε4 homozygotes may lie
in a faster rate of WMH progression, thus reaching
pathological levels earlier, compared with ε4 heterozy-
gotes and noncarriers as previously reported in longitu-
dinal studies [20, 23]. To confirm this possibility,
longitudinal follow-up of this cohort will ensue.
When correcting for the significant between-group age
differences (Model 2), we also detected a higher global
and regional WMH load in participants with a maternal
history of AD than in those with no familiar history.
These regional associations were mainly found in the
temporal and occipital lobes but were also present in
other juxtacortical areas. This finding seems to differ
from a previous report that did not observe any associ-
ation between family history and WMH burden in a
comparable cohort [27], even though the family history
classification in this previous study was performed irre-
spective of the age of onset of AD. Our finding of in-
creased WMH burden in regions that particularly
increase the risk of AD [36] may contribute to the ob-
served higher AD prevalence in individuals with a ma-
ternal family history compared with those with a
paternal one [65].
We would like to highlight that in another study per-
formed in the same ALFA cohort we found significant
effects of global and regional WMH on cognition [35].
These findings are especially important as they point out
that WMH impacts on cognition even in cognitively
normal participants, presumably by the effect of AD risk
factors. More importantly, the fact that we found a cor-
relation between higher WMH burden in the frontal
lobe and lowered executive function and memory, and
that WMH load for this same reason was impacted by
modifiable risk factors, allows us to hypothesize that
controlling modifiable AD risk factors can impact cogni-
tion mediated by WMH burden. However, a more ex-
haustive study should be performed to better understand
these links.
This study has some strengths and limitations that
should be noted. One of the strengths is the composition
of our cohort, formed by middle-aged/late middle-aged
cognitively healthy participants enriched for a family his-
tory of AD. This composition allowed us to study WMH
burden without the confounding effect of the presence
of other comorbidities. In addition, the sample contained
a relatively large number of APOE-ε4 and APOE-ε2 car-
riers, which allowed us to look for differences in WMH
load as a function of genotype. Nevertheless, the charac-
teristics of our cohort also caused some difficulties that
resulted in several limitations. The high percentage of
relatively young and WMH-free individuals resulted in a
severely skewed distribution of WMH volumes, which
prevented us from the use of parametric statistics. This
fact limited the statistical power of our analysis and
complicated the removal of confounding effects and the
assessment of interactions between different factors.
Nevertheless, this unavoidable limitation is inevitably
shared by similar studies. However, our methodological
approach allowed us to detect significant associations
without needing to dichotomize either CAIDE or WMH
load values, unlike previous studies. In addition, we used
additional statistical models accounting for the two main
drivers of WMH load: age and hypertension. This pro-
cedure allowed us to disentangle their global effect from
that of other risk factors that displayed distinct local as-
sociations with WMH load. In addition, when analyzing
other factors such as sex, APOE status, or family history,
these complementary models allowed us to correct for
between-group demographic imbalances in these two
main WMH drivers. Some previous articles presented
analyses correcting for overall lesion load as an aggre-
gated proxy of all WMH risk factors, irrespective of
whether they were measured or not. However, this pro-
cedure may lead to results more difficult to interpret
(such as an apparently negative correlation between
WMH load and age in brain regions actually not devel-
oping any lesions). On the other hand, our approach of
correcting for the two main WMH drivers reports com-
parable benefits while keeping results more directly in-
terpretable and allowing the correction of imbalances in
post-hoc group comparisons. Another obvious limitation
is the cross-sectional nature of our study, which pre-
vents us from assessing the impact of WMH load and its
longitudinal change on the clinical progression of the
studied individuals. Finally, the lack of participant amyl-
oid status is also a limitation of the study that is cur-
rently being addressed.
Conclusions
Taking our results together, we have characterized the
cerebral patterns of WMH load as a function of dementia
risk factors in a cohort of middle-aged/late middle-aged
cognitively unimpaired individuals. We found significant
correlations between global and regional patterns of
WMH load vs CAIDE percentage risk of dementia as well
as with individual risk factors. Age and hypertension were
the main drivers of the association between WMH and
CAIDE, and were associated with a widespread regional
effect pattern. Modifiable risk factors such as BMI and
hypercholesterolemia were also associated with global and
regional WMH, though to a lower degree. Unmodifiable
AD-related factors such as sex, APOE-ε2, and maternal
family history were associated with distinct regional pat-
terns of WMH that persisted after adjustment for age and
hypertension status. Our results suggest that even small
and localized levels of WMH load may increase the risk of
Salvadó et al. Alzheimer's Research & Therapy           (2019) 11:12 Page 11 of 14
late-life dementia. These findings highlight the important
effect of modifiable and nonmodifiable risk factors on
WMH even when the burden of WMH is low. Due to
their lack of other comorbidities and the young age in our
cohort, the participants in our study represent a target
population for the control of modifiable risk factors to
avoid the development of WMH and to prevent or delay
the onset of cognitive decline.
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